CD8A and myeloid sarcoma: A shift of the CD4/CD8 T cell ratio reportedly may help to differentiate between possible CD4+ T cell dysregulation in CNS autoimmunity from a cytotoxic CD8+ T cell anti-viral immune defence [40,43] and an increased B cell/monocyte ratio hinting to relapsing–remitting MS [63].